SUNSHINE PHARMA (06887) announced that on January 26, 2026, the Company entered into a strategic cooperation agreement with Shenzhen Jingtai Technology Co., Ltd. Pursuant to this agreement, the two parties intend to establish a joint venture for the purpose of building an AI-driven drug research and development platform, focusing on the following areas of collaboration.

The first initiative involves establishing a joint laboratory to co-develop innovative drug pipelines. This joint laboratory will aim for AI-driven automation, leveraging Shenzhen Jingtai's automated experimental platform technology and deployment experience to achieve a "design-build-test-learn" R&D cycle. The collaboration will focus on autoimmune diseases, with the goal of jointly discovering candidate drugs that will be advanced by the joint venture company.

The second area of focus is the joint development and promotion of large models. By combining the Company's high-quality, multi-target non-clinical data with Shenzhen Jingtai's AI algorithm platform and large model training capabilities, the partners plan to develop a PB-PK prediction large model that benchmarks against leading commercial software in the industry. Furthermore, they will jointly build an AI drug R&D engine covering the entire drug development lifecycle. Leveraging Shenzhen Jingtai's global commercial network and AI platform productization experience, the partnership will promote the Group's self-developed "HEC-SynAI Drug Synthesis Large Model" and "HEC-PharmAI Formulation Large Model," as well as a new generation PB-PK large model.

The third component is the creation of a "Model as a Service" (MaaS) business model. The parties plan to co-build an AI supercomputing platform based on a model of "computing power support + data development + ecosystem sharing." This platform will open collaborative results to academia and industry, transforming data assets and AI products into a MaaS business model.

The Board of Directors believes the strategic cooperation agreement provides a valuable opportunity for the contracting parties to utilize their respective resources and expertise, thereby creating mutual benefits and synergies. Consequently, the Board considers the execution of the agreement to be in the overall interests of the Company and its shareholders.